| Title: |
36 International neoadjuvant kidney cancer consortium guidelines on assessing pathological response after neoadjuvant therapy in kidney cancer |
| Authors: |
Jones, J; Blackmur, J; van der Mijn, K; Warren, A; Browning, L; Burgers, F; Hirsch, MS; Kapur, P; Mehra, R; Rao, P; Signoretti, S; Bex, A; Stewart, G; van Montfoort, M; members, INKCC |
| Publisher Information: |
Oxford University Press |
| Publication Year: |
2025 |
| Collection: |
Oxford University Research Archive (ORA) |
| Description: |
Background: Despite effective surgery and adjuvant immunotherapy, 1/3 of patients with initially localised renal cell carcinoma (RCC) will go on to develop relapse. Neoadjuvant therapy might improve outcomes for some of these patients; however, the approach has not been widely adopted due to a lack of prospective randomised trial data. Designing prospective neoadjuvant studies for RCC depends on properly defined clinicopathological endpoints. Pathological response is a surrogate marker of efficacy for neoadjuvant therapy in many non-renal tumour types. However, there are no standard guidelines on pathological response reporting for RCC, and correlation between pathological response following neoadjuvant therapy and survival has not been established. This study aimed to assess the status of pathological response reporting in RCC and develop a recommendation on tissue preparation and reporting for neoadjuvant RCC clinical trials. Methods: A systematic review of the PubMed and Web of Science databases was conducted to identify manuscripts reporting response to pre-surgical therapy in RCC. Guidelines for tissue preparation and pathological response reporting were reviewed at a workshop of the International Neoadjuvant Kidney Cancer Consortium (INKCC) held at the Netherlands Cancer Institute in October 2024, and further developed through expert discussions involving pathologists, surgeons, oncologists and patient advocates. Results: 119 eligible papers were identified. Of these, 27 were prospective neoadjuvant studies, 81.5% of which included a systematic assessment of pathological response across participants. However, methods varied widely between studies. Across all papers, ypT stage post treatment was reported in 34.5%, grade in 22.7%, and a quantitative assessment of residual tumour in 6.7% of manuscripts. Only 4.2% of papers provided specific methodology on tumour sampling for pathological response assessment. Key points from the INKCC guideline on pathological response assessment include:One tissue section ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://doi.org/10.1093/oncolo/oyaf276.037 |
| DOI: |
10.1093/oncolo/oyaf276.037 |
| Availability: |
https://doi.org/10.1093/oncolo/oyaf276.037; https://ora.ox.ac.uk/objects/uuid:87ee3d9f-8163-4cb7-bc0d-4328d762fca1 |
| Rights: |
info:eu-repo/semantics/openAccess ; CC Attribution-NonCommercial (CC BY-NC) |
| Accession Number: |
edsbas.B6428BA4 |
| Database: |
BASE |